Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Pharmacogenomics (London)

• Publication date

  2009-10-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/pgs.09.85PMID 19842935
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin

  2009cited by this paper
• Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans

  2008cited by this paper
• Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin

  2008cited by this paper
• Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe

  2008cited by this paper
• SLCO1B1 variants and statin-induced myopathy--a genomewide study.

  2008cited by this paper
• An improved and fully validated LC-MS/MS method for the simultaneous quantification of simvastatin and simvastatin acid in human plasma.

  2008cited by this paper
• ABCB1 Haplotypes Differentially Affect the Pharmacokinetics of the Acid and Lactone Forms of Simvastatin and Atorvastatin

  2008cited by this paper
• Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

  2007cited by this paper
• Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants

  2007cited by this paper
• Re‐evaluation and functional classification of non‐synonymous single nucleotide polymorphisms of the human ATP‐binding cassette transporter ABCG2

  2007cited by this paper
• The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins.

  2006cited by this paper
• Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics

  2006cited by this paper
• Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population

  2006cited by this paper
• Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.

  2006cited by this paper
• SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

  2006cited by this paper
• SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

  2006cited by this paper
• Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin

  2005cited by this paper
• The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid‐lowering efficacy and safety of simvastatin treatment

  2005cited by this paper
• Single nucleotide polymorphisms modify the transporter activity of ABCG2

  2005cited by this paper
• FUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA

  2005cited by this paper
• Effect of ABCG2 genotype on the oral vioavailability of topotecan

  2005cited by this paper
• Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer R

  2005cited by this paper
• Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment

  2005cited by this paper
• DISPOSITION OF ORAL AND INTRAVENOUS PRAVASTATIN IN MRP2-DEFICIENT TR– RATS

  2005cited by this paper
• Lipid-lowering response to statins is affected by CYP3A5 polymorphism.

  2004cited by this paper
• Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype

  2004cited by this paper
• Pharmacogenetic study of statin therapy and cholesterol reduction.

  2004cited by this paper
• Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction

  2004cited by this paper
• Functional Analysis of SNPs Variants of BCRP/ABCG2

  2004cited by this paper
• Functional interaction of intestinal CYP3A4 and P‐glycoprotein

  2004cited by this paper
• Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner.

  2004cited by this paper
• Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2

  2004cited by this paper
• Statin-associated myopathy.

  2003cited by this paper
• Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.

  2003cited by this paper
• C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

  2002cited by this paper
• Quantitative determination of pravastatin and its biotransformation products in human serum by turbo ion spray LC/MS/MS.

  2000cited by this paper
• Quantitation of simvastatin and its beta-hydroxy acid in human plasma by liquid-liquid cartridge extraction and liquid chromatography/tandem mass spectrometry.

  2000cited by this paper
• Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter.

  1997cited by this paper

• Association Between ABCG2 Polymorphism and Statin-Induced Adverse Events: A Meta-Analysis

  2025cites this paper
• Impacts of Pharmacokinetic Gene Polymorphisms on Steady‐State Plasma Concentrations of Simvastatin in Thai Population

  2025influential citation
• Transport of statins by multidrug resistance-associated proteins 1 and 5.

  2025cites this paper
• Pharmacokinetics and lipid-lowering efficacy affected by polymorphisms in genetic variability in statin therapy

  2025cites this paper
• Nanomolar therapeutic concentrations of statins rapidly induce cerebral artery vasoconstriction by stimulating L-type calcium channels.

  2025cites this paper
• Predicting nifedipine responses in preterm labor: a risk score incorporating ABCG2 polymorphisms and clinical factors.

  2025cites this paper
• Identification of Genetic Variants Associated with Pravastatin and Pitavastatin Pharmacokinetics

  2025cites this paper
• Assessment of Potential Drug–Drug Interactions for Novel Oral Melanocortin‐1 Receptor Agonist Dersimelagon

  2025cites this paper
• The Genetic Blueprint of Cardiovascular Therapy: Pharmacogenomics for Improved Efficacy and Safety

  2024cites this paper
• Impacts of ABCG2 loss of function variant (p. Gln141Lys, c.421 C > A, rs2231142) on lipid levels and statin efficiency: a systematic review and meta-analysis

  2024cites this paper
• Genetic Determinants of Response to Statins in Cardiovascular Diseases

  2024cites this paper
• Bioequivalence Study of Two Formulations of Simvastatin 20 mg Tablet in Healthy Filipino Participants under Fasting Conditions: A Randomized, Open-label, Two-way Crossover Study

  2024cites this paper
• Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells

  2024cites this paper
• Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review

  2024cites this paper
• When the same treatment has different response: The role of pharmacogenomics in statin therapy.

  2023cites this paper
• Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin

  2023cites this paper
• Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants

  2023cites this paper
• Simvastatin therapy in different subtypes of hypercholesterolemia - a physiologically based modelling approach

  2023cites this paper
• Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein‐mediated drug interaction?

  2023cites this paper
• Studying the right transporter at the right time: an in vitro strategy for assessing drug-drug interaction risk during drug discovery and development

  2022cites this paper
• Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open‐Label, 1‐Sequence, Crossover Studies

  2022cites this paper
• Genomewide Association Study of Simvastatin Pharmacokinetics

  2022cites this paper
• Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction

  2022cites this paper
• Pharmacogenomic mechanisms of drug toxicity

  2022cites this paper
• ABCG2 and SLCO1B1 gene polymorphisms in the Croatian population

  2022cites this paper
• Relationship between CYP2C8, UGT1A1, and ABCG2 gene polymorphisms and the exposure, efficacy, and toxicity of eltrombopag in the treatment of refractory aplastic anemia

  2022cites this paper
• Racial Disparity in Drug Disposition in the Digestive Tract

  2021cites this paper
• Simvastatin enhances the efficacy of nilotinib in chronic myeloid leukaemia by post-translational modification and drug transporter modulation

  2021cites this paper
• Medically Important Alterations in Transport Function and Trafficking of ABCG2

  2021cites this paper
• Drug Transporters: Efflux

  2021cites this paper
• ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?

  2021cites this paper
• Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins

  2021cites this paper
• Introduction to prostate cancer metabolism and treatment with nonconventional drugs

  2021cites this paper
• Modulation of Phospholipid Bilayer Properties by Simvastatin.

  2021cites this paper
• Potential role of the ABCG2-Q141K polymorphism in type 2 diabetes

  2021cites this paper
• Paracelsus Paradox and Drug Repurposing for Cancer

  2021cites this paper
• Potential clinical significance of statins on methicillin resistance reversion in Staphylococcus aureus.

  2021cites this paper
• Quantitative prediction of pharmacokinetic properties of drugs in humans: Recent advance in in vitro models to predict the impact of efflux transporters in the small intestine and blood-brain barrier.

  2021cites this paper
• Statins as adjuvants in the treatment of ovarian cancer: controversy and misunderstanding.

  2021cites this paper
• Alterations in erythrocyte membrane transporter expression levels in type 2 diabetic patients

  2021cites this paper
• BCRP/ABCG2 Transporter Regulates Accumulation of Cadmium in Kidney Cells: Role of the Q141K Variant in Modulating Nephrotoxicity

  2021cites this paper
• Comparative Hepatic and Intestinal Efflux Transport of Statins

  2021cites this paper
• Utilizing Large Electronic Medical Record Data Sets to Identify Novel Drug–Gene Interactions for Commonly Used Drugs

  2021cites this paper
• Physiologically Based Precision Dosing Approach for Drug‐Drug‐Gene Interactions: A Simvastatin Network Analysis

  2020cites this paper
• SLCO1B1 and ABCG2 Gene Polymorphisms in a Thai Population

  2020cites this paper
• Application of the Extended Clearance Classification System (ECCS) in Drug Discovery and Development: Selection of Appropriate In Vitro Tools and Clearance Prediction

  2020influential citation
• An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins

  2020cites this paper
• Simvastatin improves mitochondrial respiration in peripheral blood cells

  2020cites this paper
• Expanding the efflux in vitro assay toolbox: A CRISPR-Cas9 edited MDCK cell line with human BCRP and completely lacking canine MDR1.

  2020cites this paper
• Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin

  2020cites this paper
• PGPM_A_268457 521..530

  2020cites this paper
• Structure-Activity Relationships of Efflux Transporter Inhibitors

  2019cites this paper
• Enantiospecific Pharmacogenomics of Fluvastatin

  2019cites this paper
• Type : Article Enantiospecific pharmacogenomics of fluvastatin

  2019cites this paper
• TCRM_A_214938 921..936

  2019cites this paper
• Papel del transportador ABCG2/BCRP y sus polimorfismos en la secreción activa de compuestos a leche y su modulación a través de compuestos naturales en rumiantes

  2019influential citation
• Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2

  2019cites this paper
• The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies

  2019cites this paper
• Cellular Processing of the ABCG2 Transporter—Potential Effects on Gout and Drug Metabolism

  2019cites this paper
• Interaction Potential between Clarithromycin and Individual Statins - a Systematic Review.

  2019cites this paper
• The clinical significance of statins-macrolides interaction: comprehensive review of in vivo

  2019cites this paper
• A case of simvastatin‐induced myopathy with SLCO1B1 genetic predisposition and co‐ingestion of linagliptin and Stevia rebaudiana

  2019cites this paper
• The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics

  2019cites this paper
• Polymorphisms of the Multidrug Pump ABCG2: A Systematic Review of Their Effect on Protein Expression, Function, and Drug Pharmacokinetics

  2018influential citation
• Relevance of Breast Cancer Resistance Protein to Pharmacokinetics of Florfenicol in Chickens: A Perspective from In Vivo and In Vitro Studies

  2018cites this paper
• Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma

  2018cites this paper
• Translational physiologically-based pharmacokinetic (PBPK) modeling and simulation to support drug development and pharmacotherapy

  2018cites this paper
• Relationship between Statins Adverse Events and Pharmacokinetic Variables

  2018cites this paper
• Genetic and ethnic modulation of cardiovascular toxicity of vascular endothelial growth factor inhibitors

  2018cites this paper
• Excretory Processes in Toxicology: Drug Transporters in Drug Development

  2018cites this paper
• Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects

  2018cites this paper
• Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers

  2018cites this paper
• Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin

  2018influential citation
• The acute effects of therapeutic concentrations of simvastatin lactone on mitochondrial respiratory capacity in human skeletal muscle: the LIFESTAT study

  2018cites this paper
• Simvastatin Treatment Upregulates HO-1 in Patients with Abdominal Aortic Aneurysm but Independently of Nrf2

  2018cites this paper
• Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys

  2018influential citation
• BCRP/ABCG2 and high‐alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications

  2018cites this paper
• An update on efflux and uptake transporters as determinants of statin response

  2018cites this paper
• Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady‐state disposition of lamotrigine in adults with epilepsy

  2018cites this paper
• Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients

  2018cites this paper
• The Association between Genetic Polymorphisms and Simvastatin-Induced Myopathy: A Narrative Synthesis of Evidence

  2018cites this paper
• Interaction of Food Additives with Intestinal Efflux Transporters.

  2017cites this paper
• Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins

  2017cites this paper
• PharmGKB summary: very important pharmacogene information for ABCG2

  2017cites this paper
• Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.

  2017cites this paper
• Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants.

  2017cites this paper
• Effect of CYP2C9 *3 gene polymorphism on lipid-lowering efficacy of fluvastatin in a Chinese hyperlipidemic population

  2017cites this paper
• Simvastatin intolerance genetic determinants: some features in ethnic Uzbek patients with coronary artery disease

  2017cites this paper
• Pharmacogenetics of carboxylesterase 1

  2017influential citation
• DISTRIBUTION OF POLYMORPHISMS OF GENES OF STATINS METABOLISM AND TRANSPORT IN THE LIVER IN PATIENTS WITH CORONARY ARTERY DISEASE ETHNIC UZBEKS WITH SIMVASTATIN INTOLERANCE

  2017cites this paper
• Renal Drug Transporters and Drug Interactions

  2017cites this paper
• Estudio del mecanismo de acción de distintos quimiotipos de Lippia alba sobre el metabolismo lipídico y la proliferación celular

  2017cites this paper
• Statin-associated muscle toxicity : clinical and genomic perspectives

  2017cites this paper
• Myotoxicity of statins: Mechanism of action

  2017cites this paper
• Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia

  2017cites this paper
• Investigating DHCR24 as a protector against cellular stress : more than just a cholesterol-synthesising enzyme

  2017cites this paper
• Transporter‐Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models

  2016cites this paper
• Association between selected gene polymorphisms and statin metabolism, risk of ischemic stroke and cardiovascular disorders.

  2016cites this paper
• Pediatric Statin Administration: Navigating a Frontier with Limited Data.

  2016cites this paper
• Effect of Simvastatin, Coenzyme Q10, Resveratrol, Acetylcysteine and Acetylcarnitine on Mitochondrial Respiration.

  2016influential citation